Key Takeaways
- One-off shocks mask underlying momentum: Revenue was flat YoY, but two identifiable hits (a CMO fire costing ₹40+ crores and a GST reform transition of ₹30–32 crores) suppressed General Medicines. Adjusted for these, the business grew 5–6%.
- EBITDA margin jumped 250 bps to 34.4% despite the top-line drag, powered by cost savings, a better product mix, and a one-off ₹16 crore employee-benefit provision reversal.
- Supply constraints are fully resolved: The CMO fire remediation is complete, and management has clear visibility into normalized supply from Q3 onward.
- Oncology is live and recruiting: The Jemperli/Zejula launch on 15th August has begun enrolling patients, with good early momentum, and India is now part of global oncology trials, eliminating launch lag.
- What to watch next quarter: Whether the ₹70+ crores of one-off headwinds truly reverse into Q3 growth, the pace of oncology patient recruitment after a full quarter, and any update on the next wave of specialty pipeline assets.
General Medicines: The Quarter That Wasn't
- Two one-off hits, not a demand problem: The General Medicines portfolio declined and was flattish YoY solely because of a fire at a major CMO (₹40+ crores of product non-availability) and the transitional impact of GST reforms (₹30–32 crores). Stripping those out, adjusted growth was 5–6%.
- Competitive standing held: Mainstay brands maintained EIs in excess of 100, meaning they outperformed the market and held or gained share, except for a couple of brands directly affected by the CMO fire.
- Acute segment muted the tailwind: The July-September quarter is typically the biggest for acute portfolios, but external market growth in acute was below 5%, which dampened the usual seasonal lift across anti-infectives, pain, and dermatology.
- Promoted portfolio constrained: The promoted portfolio was driving ahead of the market with significant growth rates for key brands, but supply availability issues from the CMO prevented that momentum from converting into reported General Medicines growth.
Bhushan Akshikar: "All the remediation is behind us. So, the good news is as we speak with October behind us, we clearly have moved full stream on the remediation."
Vaccines & Specialty: The Growth Engine
- Vaccines delivered strong double-digit growth: Both the paediatric portfolio and the adult shingles vaccine grew at a strong double-digit pace, continuing a stabilization and quarter-on-quarter growth trend now running for 7–8 quarters.
- Specialty respiratory assets grew in excess of 20%: Nucala and Trelegy both sustained their trajectory of bringing benefit to patients and scaling rapidly, reinforcing the portfolio shift toward innovative, higher-growth assets.
- Oncology launch is underway with early momentum: Jemperli (endometrial cancer, second line) and Zejula (ovarian cancer) launched on 15th August with a specialized team. Patients began recruitment within the first five weeks, and momentum in the first two months has been good.
- India is embedded in global trials: 16 global GSK asset trials are running concurrently in India, and the country is part of global oncology trials. This means India faces no lag in launch timelines versus global markets.
- Patient access built in from day one: A Project Phoenix patient assistance program offers tiered pricing and affordability models for the oncology assets, with therapy costs described as in the same range as most immuno-oncology therapies.
Margins: A 250 bps Jump, With Nuance
- EBITDA margin reached 34.4%, up 250 bps YoY: The improvement came despite the flat top line, driven by strong cost savings, gross margin gains from a better product mix, and maintained field cost productivity.
- Employee cost was flattered by a one-off reversal: Employee expenses declined 8.4% YoY, but this included a ₹16 crore true-up reversal from benefits provisions where expected payouts did not materialize. Excluding that, employee costs are flat and expected to remain flat.
- Gross margin dipped seasonally, full-year improvement intact: Q2 gross margins were relatively lower than previous quarters because of the seasonal monsoon product mix, which carries lower margins. On a full-year basis, management expects gross margin improvement to be sustained, with stable raw material prices and no spike expected.
- Mix shift is not a margin threat: Imported patented products and vaccines carry lower EBITDA margins than General Medicines, but 80–85% of the portfolio is high-margin General Medicines products that are growing faster than the low-margin imported ones, so the overall margin profile is sustainable.
Juby Chandy: "80%-85% of the products are high margin products. On that context, we are not defocusing those high margin products that are growing much faster than the low margin imported products, that's where we are sustaining the margins."
Portfolio Transformation & Pipeline
- The shift toward innovative assets is structural: The company is moving to high-category-growth innovative assets (oncology launched, Nucala and Trelegy scaling), and this shift has been improving profitability over several quarters.
- New global leadership is aligned: A new global leadership team has been announced at GSK, focused on accelerating the launch of innovative assets, and India expects to continue on that trajectory.
- Next-wave pipeline is visible: A couple of assets are expected potentially in the next financial year, spanning oncology as well as some specialty areas.
- India's strategic weight is high: Within the wider GSK corporation, few countries can claim to have both endured and created impact at scale the way India has over 101 years.
Bhushan Akshikar: "Within the wider GSK family as a corporation, there are not too many countries which can boast of having not only endured but also created so much impact at scale as we have done in India."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Supply normalization | CMO fire fully remediated; all supply constraints behind the company | From Q3 FY26 onward |
| GST impact reversal | Transitionary GST reform impact (₹30–32 cr) to come back in a strong way | Q3 FY26 |
| Double-digit growth ambition | Aspiration and objective remains intact and undiluted in resourcing and wherewithal | No date (ongoing aspiration) |
| Gross margin improvement | Full-year gross margin improvement to be sustained; raw material prices stable | Full-year FY26 |
| Oncology coverage update | More details on reach and coverage to be shared once a full quarter is complete | Q3 FY26 |
| EBITDA margin sustainability | Management believes current margin levels are sustainable, with focus on expanding gross margins and cost consciousness | Ongoing |
| Next pipeline assets | A couple of assets potentially coming in oncology and specialty areas | Next financial year |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹974 cr, decline of 2.6% YoY |
| EBITDA margin | 34.4%, 250 bps improvement YoY |
| Profit after tax | 150 bps improvement YoY |
| EPS | ₹15.06, 3% improvement YoY |
| Market share | 27.6%, improving over many quarters |
| General Medicines adjusted growth | 5% to 6% (excluding fire and GST impact); declined and remained flattish on a reported basis |
| Vaccines growth | Double-digit (paediatric and adult shingles combined) |
| Speciality growth | In excess of 20% (Nucala and Trelegy combined) |
| CMO fire top-line impact | ~₹40 cr in Q2; combined Q1+Q2 impact in excess of ₹70–75 cr |
| GST transitionary impact | ₹30–32 cr in Q2 |
| Employee cost one-off reversal | ₹16 cr benefit in the quarter; employee costs flat excluding this |
| Acute segment market growth | Below 5% (Indian pharmaceutical market) |
| Oncology launch contribution | ~5 weeks of patient recruitment in Q2 following 15 August launch |
| General Medicines share of business | ~80% (or plus) of total business |